{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:27:03Z","timestamp":1791412023664,"version":"4.3.3"},"reference-count":99,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1016\/j.autrev.2010.09.012","type":"journal-article","created":{"date-parts":[[2010,9,22]],"date-time":"2010-09-22T08:45:31Z","timestamp":1285145131000},"page":"248-255","source":"Crossref","is-referenced-by-count":106,"title":["Interstitial lung disease in systemic sclerosis"],"prefix":"10.1016","volume":"10","author":[{"given":"Guillaume","family":"Bussone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Mouthon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2010.09.012_bb0005","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0755-4982(06)74924-7","article-title":"Systemic sclerosis: pathophysiology of a multifaceted disease","volume":"35","author":"Servettaz","year":"2006","journal-title":"Presse M\u00e9d"},{"key":"10.1016\/j.autrev.2010.09.012_bb0010","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1568-9972(03)00004-1","article-title":"New insights into the pathogenesis of systemic sclerosis","volume":"2","author":"Tamby","year":"2003","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2010.09.012_bb0015","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.semarthrit.2007.05.003","article-title":"Incidence and prevalence of systemic sclerosis: a systematic literature review","volume":"37","author":"Chifflot","year":"2008","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2010.09.012_bb0020","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1002\/art.11073","article-title":"Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population","volume":"48","author":"Mayes","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2010.09.012_bb0025","article-title":"Geoepidemiology of systemic sclerosis","author":"Ranque","year":"2009","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2010.09.012_bb0030","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1093\/rheumatology\/keh253","article-title":"Prevalence of systemic sclerosis in a French multi-ethnic county","volume":"43","author":"Le Guern","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2010.09.012_bb0035","first-page":"202","article-title":"Scleroderma (systemic sclerosis): classification, subsets and pathogenesis","volume":"15","author":"LeRoy","year":"1988","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2010.09.012_bb0040","first-page":"1573","article-title":"Criteria for the classification of early systemic sclerosis","volume":"28","author":"LeRoy","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2010.09.012_bb0045","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/art.1780230510","article-title":"Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee","volume":"23","year":"1980","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2010.09.012_bb0050","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/ard.2006.066068","article-title":"Changes in causes of death in systemic sclerosis, 1972\u20132002","volume":"66","author":"Steen","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2010.09.012_bb0055","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1002\/art.21433","article-title":"Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study","volume":"52","author":"Hachulla","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2010.09.012_bb0060","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1002\/1529-0131(200011)43:11<2437::AID-ANR10>3.0.CO;2-U","article-title":"Severe organ involvement in systemic sclerosis with diffuse scleroderma","volume":"43","author":"Steen","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2010.09.012_bb0065","series-title":"Maladies et syndromes syst\u00e9miques","first-page":"410","article-title":"Scl\u00e9rodermie syst\u00e9mique","author":"Mouthon","year":"2008"},{"key":"10.1016\/j.autrev.2010.09.012_bb0070","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1164\/ajrccm.165.2.ats01","article-title":"This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001","volume":"165","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.autrev.2010.09.012_bb0075","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1164\/rccm.2106012","article-title":"Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome","volume":"165","author":"Bouros","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.autrev.2010.09.012_bb0080","doi-asserted-by":"crossref","first-page":"S151","DOI":"10.1148\/radiographics.22.suppl_1.g02oc04s151","article-title":"Interstitial lung diseases associated with collagen vascular diseases: radiologic and histopathologic findings","volume":"22","author":"Kim","year":"2002","journal-title":"Radiographics"},{"key":"10.1016\/j.autrev.2010.09.012_bb0085","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1164\/ajrccm.154.2.8756813","article-title":"Bronchoalveolar lavage for evaluation and management of scleroderma disease of the lung","volume":"154","author":"Behr","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.autrev.2010.09.012_bb0090","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/art.1780400422","article-title":"Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis","volume":"40","author":"Bolster","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2010.09.012_bb0095","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1002\/1529-0131(199906)42:6<1168::AID-ANR13>3.0.CO;2-L","article-title":"Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis","volume":"42","author":"Atamas","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2010.09.012_bb0100","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1165\/ajrcmb.26.5.4683","article-title":"Gene expression in bronchoalveolar lavage cells from scleroderma patients","volume":"26","author":"Luzina","year":"2002","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.autrev.2010.09.012_bb0105","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1023\/A:1011024313525","article-title":"Peripheral blood T lymphocytes from systemic sclerosis patients show both Th1 and Th2 activation","volume":"21","author":"Valentini","year":"2001","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.autrev.2010.09.012_bb0110","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.clim.2004.01.005","article-title":"IgG reactivity with a 100-kDa tissue and endothelial cell antigen identified as topoisomerase 1 distinguishes between limited and diffuse systemic sclerosis patients","volume":"111","author":"Garcia de la Pena-Lefebvre","year":"2004","journal-title":"Clin Immunol"},{"key":"10.1016\/j.autrev.2010.09.012_bb0115","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1136\/ard.2008.104299","article-title":"Antifibroblast antibodies from systemic sclerosis patients bind to {alpha}-enolase and are associated with interstitial lung disease","volume":"69","author":"Terrier","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2010.09.012_bb0120","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1056\/NEJMoa052955","article-title":"Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis","volume":"354","author":"Baroni","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2010.09.012_bb0125","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/art.24381","article-title":"Lack of evidence of stimulatory autoantibodies to platelet-derived growth factor receptor in patients with systemic sclerosis","volume":"60","author":"Classen","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2010.09.012_bb0130","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/art.24365","article-title":"Lack of detection of agonist activity by antibodies to platelet-derived growth factor receptor alpha in a subset of normal and systemic sclerosis patient sera","volume":"60","author":"Loizos","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2010.09.012_bb0135","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1002\/1529-0131(199811)41:11<2039::AID-ART20>3.0.CO;2-1","article-title":"Inhibition of type I collagen production by dermal fibroblasts upon contact with activated T cells: different sensitivity to inhibition between systemic sclerosis and control fibroblasts","volume":"41","author":"Chizzolini","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2010.09.012_bb0140","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1002\/art.11129","article-title":"Systemic sclerosis Th2 cells inhibit collagen production by dermal fibroblasts via membrane-associated tumor necrosis factor alpha","volume":"48","author":"Chizzolini","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2010.09.012_bb0145","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1002\/art.10261","article-title":"Increased urinary F2-isoprostanes in systemic sclerosis, but not in primary Raynaud's phenomenon: effect of cold exposure","volume":"46","author":"Cracowski","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2010.09.012_bb0150","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.amjmed.2003.11.022","article-title":"Acute and sustained effects of dihydropyridine-type calcium channel antagonists on oxidative stress in systemic sclerosis","volume":"116","author":"Allanore","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.autrev.2010.09.012_bb0155","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1046\/j.1523-1747.1999.00476.x","article-title":"Monocytes of patients wiht systemic sclerosis (scleroderma) spontaneously release in vitro increased amounts of superoxide anion","volume":"112","author":"Sambo","year":"1999","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2010.09.012_bb0160","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1002\/1529-0131(200111)44:11<2653::AID-ART445>3.0.CO;2-1","article-title":"Oxidative stress in scleroderma: maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway","volume":"44","author":"Sambo","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2010.09.012_bb0165","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1164\/ajrccm.149.6.8004317","article-title":"Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis","volume":"149","author":"Wells","year":"1994","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.autrev.2010.09.012_bb0170","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/00005792-200203000-00005","article-title":"Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival","volume":"81","author":"Scussel-Lonzetti","year":"2002","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2010.09.012_bb0175","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1148\/radiology.176.3.2389033","article-title":"Interstitial lung disease in progressive systemic sclerosis: high-resolution CT versus radiography","volume":"176","author":"Schurawitzki","year":"1990","journal-title":"Radiology"},{"key":"10.1016\/j.autrev.2010.09.012_bb0180","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1378\/chest.114.6.1623","article-title":"Relationship between abnormalities on high-resolution CT and pulmonary function in systemic sclerosis","volume":"114","author":"Diot","year":"1998","journal-title":"Chest"},{"key":"10.1016\/j.autrev.2010.09.012_bb0185","first-page":"1789","article-title":"High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis","volume":"33","author":"Launay","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2010.09.012_bb0190","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1002\/art.1780370903","article-title":"Severe restrictive lung disease in systemic sclerosis","volume":"37","author":"Steen","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2010.09.012_bb0195","doi-asserted-by":"crossref","first-page":"330","DOI":"10.3899\/jrheum.080447","article-title":"Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma","volume":"36","author":"Garin","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2010.09.012_bb0200","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1148\/radiol.2322031223","article-title":"CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia","volume":"232","author":"Desai","year":"2004","journal-title":"Radiology"},{"key":"10.1016\/j.autrev.2010.09.012_bb0205","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1164\/rccm.200706-877OC","article-title":"Interstitial lung disease in systemic sclerosis: a simple staging system","volume":"177","author":"Goh","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.autrev.2010.09.012_bb0210","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/0002-9343(90)90425-D","article-title":"Evaluation and management of scleroderma lung disease using bronchoalveolar lavage","volume":"88","author":"Silver","year":"1990","journal-title":"Am J Med"},{"key":"10.1016\/j.autrev.2010.09.012_bb0215","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1002\/art.20265","article-title":"Regional differences in bronchoalveolar lavage and thoracic high-resolution computed tomography results in dyspneic patients with systemic sclerosis","volume":"50","author":"Clements","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2010.09.012_bb0220","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.semarthrit.2005.03.005","article-title":"Autoantibodies in systemic sclerosis","volume":"35","author":"Steen","year":"2005","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2010.09.012_bb0225","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.autrev.2008.06.010","article-title":"Predictive value of antinuclear autoantibodies: the lessons of the systemic sclerosis autoantibodies","volume":"7","author":"Koenig","year":"2008","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2010.09.012_bb0230","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/1529-0131(199904)42:3<465::AID-ANR11>3.0.CO;2-Y","article-title":"Influence of ethnic background on clinical and serologic features in patients with systemic sclerosis and anti-DNA topoisomerase I antibody","volume":"42","author":"Kuwana","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2010.09.012_bb0235","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1007\/BF02242456","article-title":"A longitudinal study of pulmonary function in Danish patients with systemic sclerosis","volume":"16","author":"Jacobsen","year":"1997","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2010.09.012_bb0240","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/00005792-198407000-00004","article-title":"Chemical and demographic predictors of loss of pulmonary function in systemic sclerosis","volume":"63","author":"Peters-Golden","year":"1984","journal-title":"Medicine"},{"key":"10.1016\/j.autrev.2010.09.012_bb0245","first-page":"1136","article-title":"Incidence of lung cancer in systemic sclerosis","volume":"12","author":"Peters-Golden","year":"1985","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2010.09.012_bb0250","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1002\/art.21225","article-title":"Risk of malignancy in scleroderma: a population-based cohort study","volume":"52","author":"Chatterjee","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2010.09.012_bb0255","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1210\/edrv-7-3-254","article-title":"Factors involved in the control of fibroblast proliferation by glucocorticoids: a review","volume":"7","author":"Durant","year":"1986","journal-title":"Endocr Rev"},{"key":"10.1016\/j.autrev.2010.09.012_bb0260","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/j.1365-4362.1995.tb04664.x","article-title":"Efficacy of dexamethasone pulse therapy in progressive systemic sclerosis","volume":"34","author":"Pai","year":"1995","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.autrev.2010.09.012_bb0265","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1164\/ajrccm.161.2.ats3-00","article-title":"Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS)","volume":"161","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.autrev.2010.09.012_bb0270","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1002\/1529-0131(199809)41:9<1613::AID-ART11>3.0.CO;2-O","article-title":"Case\u2013control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis","volume":"41","author":"Steen","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2010.09.012_bb0275","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1002\/art.10589","article-title":"Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial","volume":"46","author":"DeMarco","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2010.09.012_bb0280","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1136\/ard.2006.066985","article-title":"Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients","volume":"67","author":"Teixeira","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2010.09.012_bb0285","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1196\/annals.1423.029","article-title":"Interstitial lung disease associated with systemic sclerosis: what is the evidence for efficacy of cyclophosphamide?","volume":"1110","author":"Berezne","year":"2007","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.autrev.2010.09.012_bb0290","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1136\/ard.49.11.926","article-title":"5-Fluorouracil in the treatment of scleroderma: a randomised, double blind, placebo controlled international collaborative study","volume":"49","author":"Casas","year":"1990","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2010.09.012_bb0295","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1002\/art.1780361112","article-title":"The course of skin involvement in systemic sclerosis over three years in a trial of chlorambucil versus placebo","volume":"36","author":"Clements","year":"1993","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2010.09.012_bb0300","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s10067-003-0733-2","article-title":"The efficacy of oral cyclophosphamide plus prednisolone in early diffuse systemic sclerosis","volume":"22","author":"Calguneri","year":"2003","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2010.09.012_bb0305","first-page":"838","article-title":"Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease","volume":"20","author":"Silver","year":"1993","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2010.09.012_bb0310","doi-asserted-by":"crossref","first-page":"947","DOI":"10.7326\/0003-4819-132-12-200006200-00004","article-title":"Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis","volume":"132","author":"White","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2010.09.012_bb0315","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s100670050138","article-title":"Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma","volume":"18","author":"Davas","year":"1999","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2010.09.012_bb0320","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2010.09.012_bb0325","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1164\/rccm.200702-326OC","article-title":"Effects of 1-year treatment with cyclophosphamide on outcomes at 2years in scleroderma lung disease","volume":"176","author":"Tashkin","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.autrev.2010.09.012_bb0330","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1002\/art.22204","article-title":"A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma","volume":"54","author":"Hoyles","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2010.09.012_bb0335","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10067-005-1157-y","article-title":"A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis","volume":"25","author":"Nadashkevich","year":"2006","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2010.09.012_bb0340","first-page":"1064","article-title":"Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study","volume":"35","author":"Berezne","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2010.09.012_bb0345","first-page":"165","article-title":"Progressive systemic sclerosis \u2014 long-term treatment with azathioprin (author's transl)","volume":"7","author":"Maas","year":"1979","journal-title":"Immun Infekt"},{"key":"10.1016\/j.autrev.2010.09.012_bb0350","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/rheumatology\/kel244","article-title":"Mycophenolate mofetil in diffuse cutaneous systemic sclerosis\u2014a retrospective analysis","volume":"46","author":"Nihtyanova","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2010.09.012_bb0355","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1378\/chest.06-2861","article-title":"Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease","volume":"133","author":"Gerbino","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.autrev.2010.09.012_bb0360","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1097\/00062752-199911000-00008","article-title":"Hematopoietic stem cell transplantation for autoimmune disorders","volume":"6","author":"Passweg","year":"1999","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.autrev.2010.09.012_bb0365","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1146\/annurev.med.51.1.115","article-title":"New horizons in the treatment of autoimmune diseases: immunoablation and stem cell transplantation","volume":"51","author":"Marmont","year":"2000","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.autrev.2010.09.012_bb0370","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/ar102","article-title":"Immune ablation and stem-cell therapy in autoimmune disease: clinical experience","volume":"2","author":"Tyndall","year":"2000","journal-title":"Arthritis Res"},{"key":"10.1016\/j.autrev.2010.09.012_bb0375","first-page":"S392","article-title":"High-dose immunosuppressive therapy (HDIT) with autologous stem cell transplantation (SCT) for systemic sclerosis (SSc): results on the first 8 patients","volume":"43","author":"Furst","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2010.09.012_bb0380","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/S0755-4982(06)74932-6","article-title":"Therapeutic management of systemic sclerosis","volume":"35","author":"Mouthon","year":"2006","journal-title":"Presse M\u00e9d"},{"key":"10.1016\/j.autrev.2010.09.012_bb0385","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1046\/j.1365-2133.1998.02460.x","article-title":"Interferon-gamma in the treatment of systemic sclerosis: a randomized controlled multicentre trial","volume":"139","author":"Grassegger","year":"1998","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2010.09.012_bb0390","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/1529-0131(199902)42:2<299::AID-ANR12>3.0.CO;2-R","article-title":"Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial","volume":"42","author":"Black","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2010.09.012_bb0395","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/1529-0131(199906)42:6<1194::AID-ANR16>3.0.CO;2-7","article-title":"High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial","volume":"42","author":"Clements","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2010.09.012_bb0400","doi-asserted-by":"crossref","first-page":"871","DOI":"10.7326\/0003-4819-132-11-200006060-00004","article-title":"Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial","volume":"132","author":"Seibold","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2010.09.012_bb0405","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/art.1780280807","article-title":"The effect of D-penicillamine on pulmonary findings in systemic sclerosis","volume":"28","author":"Steen","year":"1985","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2010.09.012_bb0410","doi-asserted-by":"crossref","first-page":"699","DOI":"10.7326\/0003-4819-104-5-699","article-title":"The toxicity of D-penicillamine in systemic sclerosis","volume":"104","author":"Steen","year":"1986","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2010.09.012_bb0415","doi-asserted-by":"crossref","first-page":"75S","DOI":"10.1111\/1523-1747.ep12874789","article-title":"Interferons and collagen production","volume":"95","author":"Granstein","year":"1990","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2010.09.012_bb0420","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/art.1780290706","article-title":"Inhibition of excessive scleroderma fibroblast collagen production by recombinant gamma-interferon. Association with a coordinate decrease in types I and III procollagen messenger RNA levels","volume":"29","author":"Rosenbloom","year":"1986","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2010.09.012_bb0425","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0002-9343(89)80150-0","article-title":"Recombinant interferon gamma in the treatment of systemic sclerosis","volume":"87","author":"Kahan","year":"1989","journal-title":"Am J Med"},{"key":"10.1016\/j.autrev.2010.09.012_bb0430","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1002\/art.1780351005","article-title":"Treatment of systemic sclerosis with recombinant interferon-gamma. A phase I\/II clinical trial","volume":"35","author":"Freundlich","year":"1992","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2010.09.012_bb0435","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1365-2133.1992.tb11824.x","article-title":"Treatment of systemic sclerosis with gamma-interferon","volume":"126","author":"Hein","year":"1992","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2010.09.012_bb0440","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S0248-8663(05)80096-7","article-title":"Long-term results of the treatment of diffuse systemic scleroderma with interferon-gamma","volume":"14","author":"Bletry","year":"1993","journal-title":"Rev M\u00e9d Interne"},{"key":"10.1016\/j.autrev.2010.09.012_bb0445","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1136\/ard.55.10.761","article-title":"Safety and efficacy of recombinant gamma interferon in the treatment of systemic sclerosis","volume":"55","author":"Vlachoyiannopoulos","year":"1996","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2010.09.012_bb0450","first-page":"654","article-title":"A multicenter trial of recombinant human interferon gamma in patients with systemic sclerosis: effects on cutaneous fibrosis and interleukin 2 receptor levels","volume":"23","author":"Polisson","year":"1996","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2010.09.012_bb0455","doi-asserted-by":"crossref","first-page":"3954","DOI":"10.1002\/art.22264","article-title":"Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension","volume":"54","author":"Schachna","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2010.09.012_bb0460","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/art.22289","article-title":"Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I\/II trial of CAT-192","volume":"56","author":"Denton","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2010.09.012_bb0465","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1164\/rccm.200404-571OC","article-title":"Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"171","author":"Azuma","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.autrev.2010.09.012_bb0470","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1056\/NEJMoa042976","article-title":"High-dose acetylcysteine in idiopathic pulmonary fibrosis","volume":"353","author":"Demedts","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2010.09.012_bb0475","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1007\/s10067-009-1251-7","article-title":"The treatment with N-acetylcysteine of Raynaud's phenomenon and ischemic ulcers therapy in sclerodermic patients: a prospective observational study of 50 patients","volume":"28","author":"Rosato","year":"2009","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2010.09.012_bb0480","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/rheumatology\/kem357","article-title":"Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab","volume":"47","author":"McGonagle","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2010.09.012_bb0485","article-title":"Is there a role for b-cell depletion as therapy for scleroderma? A case report and review of the literature","author":"Daoussis","year":"2009","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2010.09.012_bb0490","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/rheumatology\/kep093","article-title":"Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study","volume":"49","author":"Daoussis","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2010.09.012_bb0495","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/rheumatology\/ken369","article-title":"A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide","volume":"48","author":"Sabnani","year":"2009","journal-title":"Rheumatology (Oxford)"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997210002089?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997210002089?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,7]],"date-time":"2018-12-07T23:24:43Z","timestamp":1544225083000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997210002089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":99,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["S1568997210002089"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2010.09.012","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3]]}}}